| Funding Opportunity ID: |
293494 |
| Opportunity Number: |
RFA-HL-17-023 |
| Opportunity Title: |
Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (R43/R44) |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Grant |
| Category of Funding Activity: |
Food and Nutrition
Health |
| Category Explanation: |
|
| CFDA Number(s): |
93.121
93.173
93.233
93.242
93.286
93.350
93.837
93.838
93.839
93.840
93.846
93.847
93.853
93.855
93.856
93.866
93.867 |
| Eligible Applicants: |
Small businesses |
| Additional Information on Eligibility: |
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. See Funding Announcement for Eligibility Details |
| Agency Code: |
HHS-NIH11 |
| Agency Name: |
Department of Health and Human Services
National Institutes of Health |
| Posted Date: |
Apr 28, 2017 |
| Close Date: |
Jun 26, 2017 |
| Last Updated Date: |
Apr 28, 2017 |
| Award Ceiling: |
|
| Award Floor: |
|
| Estimated Total Program Funding: |
|
| Expected Number of Awards: |
|
| Description: |
The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications from investigators with active R43/R44 Small Business Innovation Research Grants (SBIR) awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project’s approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness. |
| Version: |
Synopsis 1 |
